1. Home
  2. SMJF vs KLRS Comparison

SMJF vs KLRS Comparison

Compare SMJF & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SMJ International Holdings Inc. Class A Ordinary Shares

SMJF

SMJ International Holdings Inc. Class A Ordinary Shares

N/A

Current Price

$1.21

Market Cap

37.7M

Sector

N/A

ML Signal

N/A

Logo Kalaris Therapeutics Inc.

KLRS

Kalaris Therapeutics Inc.

N/A

Current Price

$1.34

Market Cap

44.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SMJF
KLRS
Founded
1988
2019
Country
Singapore
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
37.7M
44.5M
IPO Year
2025
2020

Fundamental Metrics

Financial Performance
Metric
SMJF
KLRS
Price
$1.21
$1.34
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
★ $16.33
AVG Volume (30 Days)
74.1K
★ 76.9K
Earning Date
12-01-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 75.70
EPS
★ N/A
N/A
Revenue
N/A
★ $165,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$68.08
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.82
$1.33
52 Week High
$11.48
$11.88

Technical Indicators

Market Signals
Indicator
SMJF
KLRS
Relative Strength Index (RSI) 34.32 27.45
Support Level $0.91 N/A
Resistance Level $3.72 $2.66
Average True Range (ATR) 0.14 0.23
MACD 0.00 -0.04
Stochastic Oscillator 5.16 2.26

Price Performance

Historical Comparison
SMJF
KLRS

About SMJF SMJ International Holdings Inc. Class A Ordinary Shares

SMJ International Holdings Inc specializes in the sale and distribution of a wide range of flooring products such as carpet tiles, polypropylene tiles, broadloom carpets, and vinyl tiles. It operates under the proprietary brand 'SMJ'. The company also supplies environmentally friendly flooring products, promoting sustainable building practices in Asia. Geographically, it has a presence across Malaysia, Indonesia, the Philippines, Vietnam, India, Singapore, and other markets. The company generates revenue mainly through the sale and distribution of its flooring products, prominently in Singapore.

About KLRS Kalaris Therapeutics Inc.

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

Share on Social Networks: